Date Title  
Jun 06, 2023
Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
 
May 12, 2023
Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
 
Mar 20, 2023
Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
 
Mar 10, 2023
Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
 
Jan 27, 2023
Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
 
Jan 27, 2023
Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
 
Nov 10, 2022
Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
 
Oct 03, 2022
Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
 
Aug 04, 2022
Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
 
Jun 02, 2022
Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
 
Displaying 1 - 10 of 97 results